Description
The
present assay system provides the quantitative determination of
13,14-dihydro-15-keto-prostaglandin-F2a
(PGFM). PGFM can be assayed in the range 0.6-150 pg/tube. Each kit
contains materials sufficient for 100 assay tubes, permitting the
construction of one standard curve and assay of 24 unknowns in
triplicate.
Introduction
Prostaglandin F2a (PGF2a)
plays an important role in various biological functions and in
pathological processes. Because of this, there are efforts in research
to obtain some correlation between PGF2a
concentration and the normal or pathological functions investigated.
Like other primary prostaglandins, however, PGF2a
is a substrate for the dehydrogenase enzyme that converts it into
13,14-dihydro-15-keto-PGF2a
(PGFM), the main metabolite found in the circulation. It is accepted
generally that the only reliable way for monitoring the endogeneous
production of prostanoids is to measure metabolites, rather than parent
compounds.
The
current PGFM RIA kit combines the advantages of radioiodine labelled
tracer 13,14-dihydro-15-keto-PGF2a-[125I]-tyrosine-methyl
ester (PGFM-[125I]TME) with a highly sensitive and specific
antibody to provide a rapid, simple and sensitive method for the
determination of PGFM concentration with about ten times as high a
sensitivity as that obtained with the most sensitive assays using
tritium-labelled tracer.
Principle of the method
This assay is
based on the competition between unlabelled PGFM and a fixed quantity of
125I-labelled PGFM for a limited number of binding sites on
PGFM specific antibody. Allowing to react a fixed amount of tracer and
antibody with different amounts of unlabelled ligand the amount of
tracer bound by the antibody will be inversely proportional to the
concentration of unlabelled ligand.
In this kit,
separation of bound from free tracer is achieved by precipitating the
bound antigen with polyethylene glycol (PEG 6000). After centrifugation
the supernatant is removed and the bound radioligand is counted in a
gamma-counter equipped with a well-type NaI (Tl) scintillation crystal.
Results obtained from the standards are used to construct a standard
dose - response curve that enables the amount of unlabelled ligand in
the sample to be calculated.
Contents of the kit
|
1 vial |
TRACER
0.3 ml per vial, containing about 75kBq PGFM-[125I]TME
in ethanolic solution |
|
1 vial |
STANDARD, lyophilised, containing 10.0 ng PGFM in buffer
with 0.01% thimerosal |
|
1 vial |
ANTISERUM, lyophilised, containing polyclonal PGFM
antiserum (rabbit) with 0.01% thimerosal. |
|
1 vial |
TRACER BUFFER, Ready to use.
10.5 ml per vial, containing 0.01% thimerosal |
|
1 bottle |
ASSAY BUFFER CONCENTRATE
15 ml per bottle , containing 0.01% thimerosal |
|
1 bottle |
POLYETHYLENE-GLYCOL 6000, SOLUTION (PEG 6000)
Ready to use.
105 ml per bottle, containing 0.01% thimerosal |
| |
Quality certificate |
| |
Pack leaflet |
Materials and equipment required
Round bottom
polystyrene or polypropylene assay tubes, about 12 x 75 mm
Test tube racks
Plastic film to cover tubes
Precision pipettes (100, 500 and 1000 µl)
Vortex mixer
Refrigerator
Refrigerated centrifuge
Gamma counter
Recommended
tools and equipment
repeating
pipettes
Preparation of reagents
125I-TRACER
One vial of the tracer concentrate contains 75 kBq of PGFM-[125I]TME
in ethanolic solution. Pour the whole quantity of the tracer buffer into
the tracer vial. The resulting solution contains 75 kBq of the tracer in
50 mM phosphate buffered saline, pH 7.3, with 0.3% gamma-globulin, 0.02%
Triton X-100 and 0.01% thimerosal. The diluted solution is stable until
expiry date, if stored at -20°C.
ANTISERUM
The antiserum was raised in rabbit agains a bovine serum albumin
conjugate of PGFM. Stored at 2-8°C, the lyophilised antiserum is stable
until expiry date.
Reconstitute the antiserum by adding 10 ml of distilled water with
gentle mixing to avoid foaming. Make ensure that the lyophilised
material is in solution. After reconstitution, the solution contains
PGFM antiserum of appropriate binding ability in 50 mM phosphate buffer,
pH 7.3, with 0.1% gelatin and 0.01% thimerosal. This solution should be
stored at 2-8°C. Under these conditions the solution is stable until at
least the date of expiry. Do not store reconstituted antiserum
deep-frozen.
STANDARD
Reconstitute the lyophilised standard by adding exactly 1.0 ml distilled
water. Make ensure that the lyophilised material is in solution. The
resulting solution contains 10 ng of PGFM per ml in 50 mM phosphate
buffer , pH 7.3 with 0.1% gelatin and 0.01% thimerosal.
Stored
at 2-8°C this stock solution is stable until the date of expiry.
The
appropriate aliquot of the standard concentrate is diluted to obtain a
series of standard dilutions according to the suggested dilution scheme
shown later. Diluted standard solutions must not be stored.
ASSAY
BUFFER CONCENTRATE
To prepare assay buffer for use in the assay system add 60 ml distilled
water to the bottle after warming it to room temperature and mix
thoroughly. The diluted assay buffer contains 50 mM phosphate buffer, pH
7.3 with 0.1% gelatin and 0.01% thimerosal.
Stored
at 2-8°C diluted buffer is stable until the date of expiry.
TRACER BUFFER
This solution contains 0.3% human gamma-globulin, 0.02% Triton X-100 and
0.01% thimerosal in 50 mM phosphate buffered saline, pH 7.3 and is
stable at 2-8°C until the date of expiry.
POLYETHYLENE-GLYCOL 6000 SOLUTION
This reagent contains 20% polyethylene-glycol (PEG 6000) in 50 mM
phospate buffer, pH 7.3, with 0.01% thimerosal as preservative. Stored
at 2-8°C, the solution is stable until the date of expiry
Preparation of samples prior to assay
Contrary to primary prostaglandins whose concentrations increase rapidly
when tissues are injured, „de novo” prostanoid syntesis does not usually
alter the physiological levels of prostaglandin metabolites therefore
the sampling procedure does not need any special precaution. However the
general problem of radioimmunoassay, i. e. that the inhibition of
binding to the antibody can be affected by factors other than the
analyte concentration itself holds for PGFM RIA, too. Because of this,
preparation of samples prior to assay is a prerequisite to the
radioimmunological determination of prostaglandins. Out of the various
useful sample preparation methods, the most reliable solid-phase
extraction technique using Sep-Pak C18 Cartridges (Waters
Ass.) has been applied succesfully in our laboratory with a slight
modification of the Powell’s method for preparation of human plasma
samples prior to radioimmunoassay. This procedure is provided for
guidance only, and it remains the investigator’s responsibility to
validate his experimental method.
Extraction on
Sep-Pak C18 Cartridges
|
1 |
Pretreat the cartridge according to manufacturer’s
instructions. |
|
2 |
Dilute 1 ml plasma with 4 ml water, then acidify to pH
3.0 with the addition of about 100 µl 2 M citric acid (Check pH
individually, if needed). |
|
3 |
Apply sample to the cartridge with a syringe and pass
through with gentle pressure (about 1 ml/min). |
|
4 |
Wash with 10 ml water. |
|
5 |
Wash with 10 ml 10% ethanol. |
|
6 |
Wash with 10 ml petroleum ether or n-hexane. |
|
7 |
Elute PG-s with 10 ml ethyl-acetate. |
|
8 |
Add 1 ml water to ethyl-acetate, shake, and separate the
water phase. Repeat this procedure once again. |
|
9 |
Dry the ethyl-acetate extract under vacuum at room
temperature. |
|
10 |
Dissolve the residue in assay buffer and measure PG-level
immediately. If RIA measure cannot be performed immediately,
store samples in ethylacetate below -2°C and proceed with steps
9-10 immediately before the assay. |
Using
this method the extraction efficiency is over 90%, thus the measurement
of this value by adding labelled marker may generally be omitted.
Precaution: Plasma or serum samples cannot by any means be assayed
directly.
Warning! Never use the cartridges more than once with plasma
samples.
Assay procedure
Preparation of PGFM working standards
To prepare standard dilution assay buffer provided with the kit must be
used. The suggested dilution scheme to cover a standard curve range of
0.6 to 150 pg is shown in Table 1.
Table 1. Dilution scheme
|
Tube |
volume
of the standard dilution |
volume
of assay buffer |
Amount
of standard (pg/tube) |
|
s |
|
|
1000 |
|
A |
150 of
sol. s |
850 |
150 |
|
B |
200 of
sol. A |
400 |
50 |
|
C |
200 of
sol. B |
400 |
16.7 |
|
D |
200 of
sol. C |
400 |
5.6 |
|
E |
200 of
sol. D |
400 |
1.9 |
|
F |
200 of
sol. E |
400 |
0.6 |
Vial
"s" is prepared by reconstituting the lyophilised standard with 1.0 ml
distilled water.
Note: All volumes are in microliter.
Radioimmunoassay protocol
For a quick
guide refer to Table 2.
Day 1
|
1 |
Prepare all reagents as described previously prior to
performing the assay. |
|
2 |
Equilibrate all reagents except PEG 6000 solution to room
temperature and mix before use. (Refer to Table 2. for steps
3-16.) |
|
3 |
Label triplicate tubes according to Table 2.
(Determinations can equally be performed using duplicates.) |
|
4 |
Pipette 300 µl of assay buffer into tubes 4-6
(non-specific binding tubes) |
|
5 |
Pipette 200 µl of assay buffer into tubes 7-9 (total
bound or zero standard tubes) |
|
6 |
Pipette 100 µl of assay buffer into all remaining tubes
except 1-3 (total count tubes) |
|
7 |
Pipette 100 µl of each diluted standard in triplicate (A
through F into tubes 10-27). |
|
8 |
Pipette 100 µl of each sample in triplicate into tubes
28-100. |
|
9 |
Pipette 100 µl of tracer solution into each tube. |
|
10 |
Pipette 100 µl of antiserum into all tubes except 1-6 and
vortex throughly for 2-5 seconds. (Note: If drops remained on
the wall of tubes after vortexing, centrifuge the tubes at 1000
x g for a few seconds.) |
|
11 |
Incubate the tubes at 4°C overnight (16-20 hours). |
Day 2
|
12 |
Shake the cold PEG 6000 solution vigorously and pipette 1
ml into tubes 4-100. Vortex the tubes for a few seconds. |
|
13 |
Equilibrate the tubes at 4°C for 10 minutes. |
|
14 |
Centrifuge the tubes at 4°C and 2000 xg for 20 minutes.
See Note 1. |
|
15 |
Remove the supernatant (See Note 2) |
|
16 |
Count the radioactivity for at least 60 seconds in a
gamma-counter. |
|
17 |
Calculate the concentrations as described in
Calculation of results. |
Note 1.
g = 1.118 x 10-5x(rpm)2 x (arm-length of the
centrifuge in cm). The tubes should be centrifuged for a longer time or
at a higher rpm, if the supernatant is not clear enough.
Note 2.
The supernatant can be decanted provided that drops are removed from the
wall of tube. However, aspiration with the aid of a simple plastic tip
is more convenient. Care should be taken not to stir up the precipitate.
Table 2.
Assay Protocol, Pipetting Guide (all volumes in microliters)
|
Tubes
Reagents |
Total count
1-3 |
Non specific binding
4-6 |
Zero
standard
7-9 |
Standard
A-F
10-27 |
Sample
28-100 |
|
Buffer |
|
300 |
200 |
100 |
100 |
|
Standard |
|
|
|
100 |
|
|
Sample |
|
|
|
|
100 |
|
Tracer |
100 |
100 |
100 |
100 |
100 |
|
Antiserum |
|
|
100 |
100 |
100 |
|
Vortex mix
Incubate overnight (16-20 hours) at 4oC |
|
PEG
6000 |
|
1000 |
1000 |
1000 |
1000 |
|
Vortex mix
Incubate for 10 minutes at 4°C |
|
Centrifuge for 20 minutes at 4oC and 2000 xg |
|
Remove
the supernatant. |
|
Count
all tubes |
Calculation of results
The
calculation is illustrated using representative data. The assay data
collected should be similar to those shown in Table 3.
Calculate the average counts per minute (CPM) for each triplicate of
assay tubes.
Calculate the percent B0 / T for zero standard (S0)
by using the following equation:
| |
S0 cpm – NSB cpm |
|
|
% B0 / T = |
——————— |
x 100 |
| |
T cpm – NSB cpm |
|
Calculate the
normalized percent binding for each standard and sample by using the
following equation:
| |
SA-F / sample cpm – NSB cpm |
|
|
% B / B0 = |
———————————— |
x 100 |
| |
S0 cpm – NSB cpm |
|
Using
semi-logarithmic graph paper plot B / B0 % for each standard
versus the corresponding concentration of PGFM. Figure 1 shows a typical
standard curve.
Determine the PGFM concentration of the unknown samples by interpolation
from the standard curve. Do not extrapolate values beyond the standard
curve range.
Table 3. Typical Assay Data
|
Tubes |
Tube
No |
Count
cpm |
Average
cpm |
Average
net cpm |
B / B0
% |
|
Total |
1
2
3 |
25065
24016
24444 |
24508 |
23528 |
|
|
Non-specific binding |
4
5
6 |
939
971
1030 |
980 |
|
|
|
S0
0 pg/tube |
7
8
9 |
13873
14320
13625 |
13939 |
12959 |
100 |
|
SA
0.6 pg/tube |
10
11
12 |
13093
13472
13057 |
13207 |
12227 |
94.4 |
|
SB
1.9 pg/tube |
13
14
15 |
11840
12147
12688 |
12225 |
11245 |
86.8 |
|
SC
5.6 pg/tube |
16
17
18 |
9558
9675
9804 |
9679 |
8699 |
67.1 |
|
SD
16.7 pg/tube |
19
20
21 |
6854
7144
7084 |
7027 |
6047 |
46.7 |
|
SE
50 pg/tube |
22
23
24 |
4851
4928
4768 |
24849 |
3869 |
29.9 |
|
SF
150 pg/tube |
25
26
27 |
3266
3376
3381 |
3341 |
2361 |
18.2 |

PGFM concentration pg/tube
Figure 1.
A typical standard curve
(Do not use to calculate sample values)
Characterization of the assay
Assay
parameters
|
NSB / T |
|
< 5% |
|
B0 / T |
|
50 ± 10 % |
|
ED-50 |
|
14.9 ± 2.9 pg/tube |
Specificity
Cross
reactivity was defined in per cent by weight at the 50% displacement
level.
|
13,14-dihydro-6,15-diketo-PGE2 |
2.6% |
|
13,14-dihydro-15-keto-PGE2 |
0.1% |
|
PGA2 |
0.001% |
|
PGD2 |
<
0.001% |
|
PGE1 |
<
0.001% |
|
PGE2 |
<
0.001% |
|
PGF1a |
<
0.001% |
|
PGF2a |
<
0.001% |
|
6-keto-PGF1a |
<
0.001% |
|
6-keto-PGE1 |
<
0.001% |
|
Thromboxane B2 |
<
0.001% |
Additional information
Storage
Store
this kit between 2 and 8°C.
Availability
From stock.
Shelf life
The shelf life
of kit reagents is 8 weeks from the date of manufacturing. The actual
expiry date is given on package label and in the quality certificate.
Components from various lots or from kits of different manufacturers
should not be mixed or interchanged.
Precautions and warnings
This kit
should only be used for research purposes.
Radioactivity
This kit
contains radioactive material. Receipt, acquisition, possession, or use
of radioactive materials are subject to regulations, and a licence of
(inter)national authorizing bodies. It is the responsibility of the user
to ensure that local regulations or codes of practice are satisfied |